45 completed, 9 terminated, 8 unknown, 3 withdrawn. 68 Phase 1, 25 Phase 2.
Follow Metaplasia: new trials by email Literature Review of Metaplasia trials Research Report on Metaplasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Study of Intrastromal Anti-VEGF Injection for Corneal Neovascularization. Intrastromal anti-VEGF injection and topical antiviral eye drops, Conventional antiviral topical ocular drops. - Herpes Simplex Keratitis, Corneal Neovascularization | Phase 1 / Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2025-10-01 | 2026-01-09 |
| NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration NG101 AAV gene therapy - Age-Related Macular Degeneration | Phase 1 / Phase 2 | Active not recruiting | Elisigen, Inc. | 20 | 2023-09-08 | 2026-09-10 |
| Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor Trametinib treatment, Endoscopy - Gastric Cancer, Metaplasia | Phase 1 | Unknown | Vanderbilt-Ingram Cancer Center | 15 | 2022-11-09 | 2024-07-31 |
| The Safety and Efficacy of KDR2-2 Suspension Eye Drops in the Treatment of Corneal Neovascularization KDR2-2 suspension eye drops - Corneal Neovascularization | Phase 1 / Phase 2 | Unknown | Zhongshan Ophthalmic Center, Sun Yat-sen University | 60 | 2021-08-10 | 2021-08-18 |
| KDR2-2 Suspension Eyedrop in the Treatment of Neovascular Glaucoma (KDR-NVG) Trial 4mg/ml KDR2-2 suspension eyedrop, 16mg/ml KDR2-2 suspension eyedrop - Neovascular Glaucoma, Neovascularization | Phase 1 | Active not recruiting | Sun Yat-sen University | 40 | 2021-04-19 | 2024-12-11 |
| Safety, Tolerability and Pharmacokinetic Profile of SYL1801 Eye Drops SYL18001 sodium Low dose q.d, SYL18001 sodium Middle dose q.d, SYL18001 sodium High dose q.d - Safety, Tolerability and Pharmacokinetic Profile in Healthy Volunteers, Choroidal Neovascularization | Phase 1 | Completed | Sylentis, S.A. | 36 | 2021-03-17 | 2022-03-31 |
| Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment KDR2-2, Placebo - Corneal Neovascularization | Phase 1 | Unknown | Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd | 62 | 2020-08-26 | 2020-11-06 |
| An Exploratory Clinical Trial Evaluating the Tolerability and Efficacy of KH906 in Patients With Corneal Neovascularization Conbercept eye drop, Placebo - Corneal Neovascularization | Phase 1 | Unknown | Chengdu Kanghong Biotech Co., Ltd. | 39 | 2019-07-18 | 2020-01-02 |
| A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration GB-102, Aflibercept - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Graybug Vision | 32 | 2017-08-29 | 2019-12-20 |
| Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization Aflibercept - Corneal Neovascularization | Phase 1 / Phase 2 | Terminated | Rabin Medical Center | 6 | 2017-03-02 | 2019-09-16 |
| Limbal Stem Cell Deficiency (LSCD) Treatment With Cultivated Stem Cell (CALEC) Graft Biopsy to collect limbal epithelial stem cells that will be cultivated into a graft, Cultivation of Limbal epithelial cells into a graft, CALEC Transplant - Limbal Stem Cell Deficiency | Phase 1 / Phase 2 | Completed | Massachusetts Eye and Ear Infirmary | 23 | 2016-08-01 | 2025-01-15 |
| Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD OPT-302, Lucentis™ - Eye Diseases, Macular Degeneration | Phase 1 | Completed | Opthea Limited | 51 | 2015-07-01 | 2017-11-06 |
| Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration Aflibercept - Neovascular Macular Degeneration | Phase 1 | Completed | University of Nebraska | 5 | 2014-09-05 | 2023-09-06 |
| Safety and Efficacy of Autologous Bone Marrow Stem Cells for Lower Extremity Ischemia Treating BM-MNC injection - Lower Extremity Ischemia, Leg Ulcer | Phase 1 / Phase 2 | Unknown | Pontifícia Universidade Católica do Paraná | 60 | 2014-09-01 | 2017-12-13 |
| Subconjunctival IVIg (Gamunex-C) Injection for Corneal Neovascularization and Inflammatory Conditions Gamunex-C - Corneal Neovascularization, Corneal Graft Failure | Phase 1 | Withdrawn | University of Utah | 2014-07-01 | 2016-08-05 | |
| A Multi-Center Study of the Safety and Efficacy of Bevacizumab in High-Risk Corneal Transplant Survival Avastin® (bevacizumab), 0.9% NaCl & Refresh Liquigel - Corneal Neovascularization, Corneal Graft Failure | Phase 1 / Phase 2 | Completed | Reza Dana, MD | 75 | 2014-04-01 | 2020-08-10 |
| 68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis 68Ga-NODAGA-RGD PET/CT, 18F-FDG PET/CT, 18F-FET PET/CT - Pathological Angiogenesis | Phase 1 | Terminated | University of Lausanne Hospitals | 42 | 2014-03-01 | 2024-06-20 |
| Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea Subconjunctival aflibercept, Placebo: Standard of care only - Corneal Neovascularization | Phase 1 | Terminated | Balamurali Ambati | 2 | 2013-06-01 | 2015-10-07 |
| Pharmacokinetics of CLG561 in Patients With Advanced Age-Related Macular Degeneration CLG561 - Age-related Macular Degeneration | Phase 1 | Completed | Alcon Research | 50 | 2013-05-01 | 2016-03-25 |
| Sildenafil Trial in Children and Young Adults With CF Sildenafil - Cystic Fibrosis With Mild to Moderate Lung Disease, CMRI of Lung Perfusion | Phase 1 / Phase 2 | Withdrawn | Children's Hospital Medical Center, Cincinnati | 2012-08-01 | 2012-12-11 |
Showing 20 of 68. Sign in to see all of them.
Choroidal Neovascularization (34) · Macular Degeneration (28) · Corneal Neovascularization (15) · Neovascularization, Pathologic (14) · Polypoidal Choroidal Vasculopathy (7) · Eye Diseases (5) · Retinal Degeneration (5) · Retinal Diseases (5) · Diabetic Retinopathy (4) · Wet Macular Degeneration (3) · Geographic Atrophy (2) · Inflammation (2) · Lung Neoplasms (2) · Macular Edema (2)
Pathologic Processes (68) · Pathological Conditions, Signs and Symptoms (68) · Eye Diseases (54) · Neovascularization, Pathologic (52) · Choroid Diseases (38) · Uveal Diseases (38) · Retinal Diseases (29) · Retinal Degeneration (24) · Corneal Diseases (14) · Cardiovascular Diseases (7) · Eye Diseases, Hereditary (6) · Vascular Diseases (6) · Diabetes Complications (5) · Diabetic Angiopathies (5)
Ranibizumab (18) · aflibercept (5) · Bevacizumab (4) · Triamcinolone Acetonide (3) · pazopanib (3) · Carboxymethylcellulose Sodium (2) · Intravitreal Injections (2) · S 3304 (2) · Sodium Chloride (2) · Adalimumab (1) · Adrenal Cortex Hormones (1) · Cerebral Angiography (1) · Endoscopy (1) · Erlotinib Hydrochloride (1) · Hizentra (1)
National Eye Institute (NEI) (6) · Reza Dana, MD (5) · GlaxoSmithKline (3) · Johns Hopkins University (3) · Chengdu Kanghong Biotech Co., Ltd. (2) · Hawaii Pacific Health (2) · Massachusetts Eye and Ear Infirmary (2) · National Cancer Institute (NCI) (2) · Shionogi (2) · Southeast Retina Center, Georgia (2) · Alcon Research (1) · Allergan (1) · Balamurali Ambati (1) · Children's Hospital Medical Center, Cincinnati (1) · Clement K. Chan (1)
United States (50) · China (5) · Israel (2) · Australia (1) · Brazil (1) · Canada (1) · Italy (1) · Japan (1) · Lebanon (1) · Spain (1) · Switzerland (1)
Reza Dana, MD, MPH, MSc (4) · Dennis M. Marcus, M.D. (2) · Gregg T Kokame, MD, MMM (2) · Quan D Nguyen, MD, MSc (2) · Reza Dana, M.D., MPH (2) · Balamurali Ambati, M.D., Ph.D., M.B.A. (1) · Balamurali K Ambati, M.D., Ph.D., M.B.A. (1) · Charles P. Semba, MD (1) · Christopher D Riemann, MD (1) · Clement K Chan, M.D. (1) · Diana V Do, MD (1) · Gary Krasner, PhD (1) · Glenn Stoller, MD (1)
PMID 24113783, PMID 39207600, PMID 17404091, PMID 18054887, PMID 19211094, PMID 19365012, PMID 19549103, PMID 19726427, PMID 19936307, PMID 20136420, PMID 20609706, PMID 20827138, PMID 21555610, PMID 22967868, PMID 22990319, PMID 23233252, PMID 23316779, PMID 25277305, PMID 25376617, PMID 26114826, PMID 26431823, PMID 27020759, PMID 27124775, PMID 27865764, PMID 28526489, PMID 32382869, PMID 36720731, PMID 40038272, PMID 40152603
N01CN35157 (1), P30CA060553 (1)